Democrats in the House of Representatives will introduce a bill today that seeks to reaffirm the authority of the FDA on drug approvals, after a Texas court held that the
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed
Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t
Eisai has reached an agreement with Japan’s National Cancer Centre to run a trial of its EZH2 inhibitor Tazverik in young people with cancers who either have no drug treat
A pair of licensing deals today for BioNTech and Takeda provide further examples that antibody-drug conjugates (ADCs) are cementing their place as in the biopharma armamen
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.